SCHEMBL10153335

SCHEMBL10153335

c1ccc(CC2CCC3(CCNCC3)O2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.49
NAMPT P43490 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HIF1A Q16665 1/20 0.39
POLB P06746 1/20 0.38
OPRD1 P41143 1/20 0.38
HTR1A P08908 2/20 0.37
TACR1 P25103 1/20 0.37
GRM2 Q14416 1/20 0.37
OPRM1 P35372 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783552 0.72 NAMPT (0.37) NAMPT
SCHEMBL15100048 0.72 NAMPT (0.37) NAMPT
SCHEMBL10153337 0.72 GBA1 (0.53) GBA1NAMPTMEN1ALDH1A1CYP2C9
SCHEMBL2360268 0.72 SIGMAR1 (0.57)
SCHEMBL21077897 0.71 NAMPT (0.34) NAMPT
SCHEMBL20504480 0.71 SLC6A2 (0.39) GBA1NAMPTSLC6A2SLC6A4SLC6A3
SCHEMBL24508103 0.69 SLC6A2 (0.37) GBA1SLC6A2SLC6A4SLC6A3HTR1A
SCHEMBL6824251 0.68 SIGMAR1 (0.58) MEN1ALDH1A1CYP2C9TSHRCYP2C19
SCHEMBL6773993 0.68 SIGMAR1 (0.58) MEN1ALDH1A1CYP2C9TSHRCYP2C19
SCHEMBL21078320 0.67 NAMPT (0.39) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140275017-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-09-18 US disclosed
US-20140275017-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-09-18 US disclosed
US-8778957-B2 CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2014-07-15 US disclosed
US-8778957-B2 CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2014-07-15 US disclosed
US-20120010193-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2012-01-12 US disclosed
US-20120010193-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275017-A1 CGRP RECEPTOR ANTAGONISTS BDKRB1, CALCRL, BDKRB2 GBA1 1842/4885NAMPT 3203/4885SLC6A2 1219/4885
US-20120010193-A1 CGRP RECEPTOR ANTAGONISTS BDKRB1, BDKRB2, CALCRL GBA1 1849/4885NAMPT 3131/4885SLC6A2 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.